May 12 is ME/CFS Awareness Day. Fuel progress all month long—join the May Momentum campaign!
Precision research program to identify the unique biology of individuals and the unifying biological pathways of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS)
Established in 2020, the Melbourne ME/CFS Collaboration, directed by Christopher W. Armstrong, PhD, is a hub of research innovation and collaboration for ME/CFS and related conditions.
Dr. Armstrong’s interest in ME/CFS research was sparked by his interactions with patients and clinicians during his PhD in Biochemistry at The University of Melbourne, leading to a dedicated pursuit of understanding these complex diseases.
Latest Video
His innovative use of metabolomics to detect biochemical changes in patients was pivotal, capturing Linda Tannenbaum’s attention at a conference and resulting in his collaboration with Open Medicine Foundation (OMF) as a Science Liaison and a Visiting Scholar at Stanford University under Ronald W. Davis. This collaboration laid the foundation for OMF Australia, established to continue supporting Chris’ groundbreaking research upon his return to Melbourne.
The Melbourne ME/CFS Collaboration aims to decipher the common biological pathways in ME/CFS, acknowledging patient diversity in disease manifestation. Initially focusing on metabolic studies, the collaboration now champions precision medicine to understand each patient’s unique biology. Dr. Armstrong’s strategy includes expanding research networks within Australia and across the world, guiding new scientists in the field and bridging different patient groups to enhance collective understanding.
Under Dr. Armstrong’s leadership, the Melbourne ME/CFS Collaboration continues to be at the forefront of cutting-edge research, striving to unlock the complexities of ME/CFS and pave the way for targeted interventions and improved patient outcomes.
The purpose of this study is to facilitate early detection of ME/CFS in people with Long COVID and better understand disease progression.
The study aims to compare the effectiveness of different saline formulations, including a placebo, in individuals with ME/CFS, Long COVID, and POTS, to determine the most beneficial types and understand their impact on patient improvement.
To carry out these ambitious projects, Dr. Armstrong is establishing networks and collaborations extending to USA, UK, Sweden, and other Australian institutions.
University of Melbourne, Australia
Paul Gooley, PhD
Natalie Thomas, PhD
Kathy Huang
Amber Jaa-Kwee
Elena Christopolous
Xiaoyun Wang, PhD
David Fineberg, MBBS, FRACGP, DCH
Neil McGregor, PhD
David Ascher, PhD
Elisha Josev, PhD
Sarah Knight, PhD
Adam Scheinberg, FRACP, FAFRM, MMed(ClinEpi)
Elena Schneider-Futschik, PhD
Kristin Brown, PhD
Michael Menden, PhD
Leigh Johnston, PhD
Rebecca Glarin, BApSc, PGDip(MRI)
Rob Williams
Bradford Moffat, PhD
Christopher Rowe, BMBS, FRACP, MD, FAANMS
Stanford University, USA
Ronald Davis, PhD
Michael Snyder, PhD
Robert Phair, PhD
Laurel Crosby, PhD
Jaime Seltzer
Linda Lan, PhD
Yue Wu, PhD
Jessi Li
Longsha, Liu
Harvard-Affiliated Hospitals, USA
David Systrom, MD
Wenzhong Xiao, PhD
Uppsala University, Sweden
Jonas Bergquist, MD, PhD
University of Montreal, Canada
Alain Moreau, PhD
University of Alabama Birmingham, USA
Jarred Younger, PhD
University College London, UK
Jo Cambridge, PhD
Massachusetts Institute of Technology, USA
Michal Tal, PhD
Beth Pollack
La Trobe University, Australia
Sarah Annesley, PhD
Paul Fisher, PhD
Daniel Missailidis, PhD
Australian National University, Australia
Brett Lidbury, PhD
Alice Richardson, PhD
Monash University, Australia
Joanne Fielding, PhD
Meaghan Clough, PhD
Caroline Gurvich, Dpsych
Jade Bartholomew
Macquarie University, Australia
Benjamin Heng, PhD
Baker Institute, Australia
Keegan Moneghetti, FRACP, PhD
Murdoch Children’s Research Institute, Australia
Tracey Chau, PhD
Victoria University, Australia
Joshua Johnson, PhD
South Australian Health and Medical Research Institute (SAHMRI), Australia
Martin Lewis, PhD
Michael Musker, PhD
Please help us expand our research efforts across the globe. Every donation brings us closer to a fully-funded research effort and the answers we all seek.
OMF Australia is a Public Ancillary Fund, established for the purpose of promoting and funding research into chronic complex diseases, and supports the Melbourne ME/CFS Collaboration.
